Abstract
Schrodinger Inc. will report third-quarter 2026 financial results on November 4, 2026 Post-Mkt; this preview outlines consensus projections, reviews last quarter’s performance, and assesses near-term drivers for revenue, margins, net income, and adjusted EPS.
Market Forecast
Current projections indicate third-quarter revenue of 47.26 million US dollars, implying a year-over-year decline of 8.34%, with an estimated adjusted EPS of -0.70 and EBIT of -52.24 million; the EPS estimate suggests a modest 1.48% improvement year over year, while margin guidance has not been provided. With margin forecasts not disclosed, investors will focus on how the mix of software subscriptions versus collaboration and milestone revenue shapes gross profitability and the net income line compared with last quarter’s margin profile.
Schrodinger Inc.’s main business remains the two-pronged model of software and drug discovery collaborations; the company’s software backlog and enterprise deployments frame a stable base, while collaboration payments can be lumpy and influence quarter-to-quarter comparability. The most promising near-term growth vector appears to be drug discovery partnerships and asset monetization, underpinned by recent partnership activity; last quarter this segment contributed 23.42 million US dollars, and the trajectory will hinge on timing of milestones and progress updates year over year.
Last Quarter Review
Schrodinger Inc. delivered second-quarter revenue of 58.89 million US dollars, a gross profit margin of 55.07%, GAAP net profit attributable to the parent company of 5.98 million US dollars, a net profit margin of 10.15%, and adjusted EPS of 0.08, up 113.56% year over year. A notable highlight was EBIT of -41.55 million, which was less negative than projections, signaling operating discipline despite the mix of software and collaboration revenue in the quarter. The main business mix featured 35.47 million US dollars from software and 23.42 million US dollars from drug discovery collaborations, with total revenue rising 7.54% year over year.
Current Quarter Outlook
Software subscriptions and enterprise deployments
The near-term setup for software hinges on closing activity in enterprise renewals and expansions, the pace of deployment for large accounts, and the transition dynamics around managed or cloud-delivered offerings. Following a 35.47 million US dollar contribution last quarter, the quarter-on-quarter pattern for software can be influenced by multi-year contract timing, annual billing cycles, and any pull-forward or push-out of deals; this creates variability that consensus attempts to smooth but cannot fully anticipate. With the total company revenue estimate at 47.26 million US dollars, the model implies a sequential step-down from the second quarter; that step-down often reflects fewer milestone events or a softer collaboration contribution rather than a structural change in the software base, but it also requires management to execute on late-quarter software closes to meet internal targets. New or expanded enterprise initiatives, including deployments tied to large pharmaceutical customers, can bolster the subscription book and annualized contract value, yet these projects frequently translate into reported revenue gradually, given recognition policies and phased rollouts. Investors will track commentary on pipeline quality, win rates, and renewal pricing to gauge durability of the software growth algorithm and assess whether quarter-end activity supports consensus or creates a setup for a modest under- or outperformance.
Drug discovery collaborations and asset monetization
Collaboration and milestone revenue remains the single largest swing factor for quarterly outcomes, and it is also where upside can crystallize quickly if development milestones are achieved or if new licensing arrangements are finalized. Last quarter’s 23.42 million US dollars from this segment established a healthy base, but management has consistently cautioned on timing variability; therefore, a sequential cooling in total revenue for the third quarter would not be surprising in the absence of milestones. Since the beginning of the year, the company has advanced partnership activity and portfolio structuring that could seed future milestone and royalty streams, including the creation of Tectora Therapeutics with partners and a licensing collaboration framework designed to progress immunology and inflammation projects; such arrangements rarely deliver immediate large revenue, but they can catalyze milestone receipts later in the calendar. Separately, further software-enabled discovery deployments with major pharma partners are designed to improve throughput and probability of success across partnered programs, and successful early-phase readouts or progression gates in those programs would unlock milestone recognition that could alter the quarterly cadence. The consensus revenue decline of 8.34% year over year for the third quarter embeds a cautious stance on these events; any evidence of incremental milestones, option exercises, or asset monetization could lend upside to both revenue and earnings relative to the baseline.
Stock-price drivers: earnings quality, margin signals, and forward guardrails
The stock’s reaction often correlates less with headline revenue and more with the quality of earnings, operating expense control, and visibility into the next two to three quarters. The EBIT estimate of -52.24 million US dollars sets a low bar given year-over-year improvement implied by projections; investors will parse commentary on operating expense run-rate, hiring plans, and clinical or preclinical spend concentration to evaluate whether the company can sustain the cost discipline that helped the prior quarter outperform expectations. On the margin side, last quarter’s 55.07% gross profit margin provides a reference point; if the mix skews toward software, gross margin resilience can support a smaller EPS loss than the -0.70 estimate, while collaboration-heavy prints can compress margins but may deliver absolute revenue upside through milestone payments. Because management typically emphasizes annual patterns rather than single-quarter targets, traders will watch for any update to the full-year revenue and cash use cadence; even a reaffirmation can be supportive if the third quarter print aligns with the seasonal curve implied at midyear. Finally, indications around active negotiations for new collaborations, program advancement timelines in partnered assets, and any steps toward monetization of portfolio companies could be meaningful catalysts that shift the earnings trajectory beyond the quarter, indirectly informing valuation multiples used by the market.
Analyst Opinions
Bullish views outnumber bearish ones among the captured notes during the period, with directional Buy/Overweight stances outweighing Sell calls by a ratio of 100% to 0%. One highlighted example is KeyBanc’s Scott Schoenhaus, who reiterated a Buy rating with a 20.00 US dollars price target, pointing to the multi-year opportunity supported by recurring software revenue and the optionality embedded in collaboration and milestone economics. Broader coverage leans positive as well, with an average stance tilted toward Overweight and a mean price target in the low 20s, reflecting expectations that execution on software renewals and the maturation of partnered programs can create a path to revenue growth reacceleration and improved earnings power.
The bullish case centers on several near-term markers. First, last quarter’s upside on both revenue and adjusted EPS provided evidence that the expense base and operating intensity are now better aligned to revenue seasonality, lowering the threshold for incremental operating leverage if top-line trends stabilize. Second, the current-quarter model already assumes an 8.34% year-over-year revenue contraction, which sets a conservative hurdle; any surprise milestone recognition or stronger-than-expected software closings would likely drive positive revisions to the EPS estimate of -0.70. Third, the partnership pipeline has been active year to date, and although such relationships typically contribute revenue on a lag, investors see a growing base of shots on goal that could translate into milestones over the next several quarters, enhancing visibility and diversifying the earnings stream. In this framework, bullish analysts view the third quarter as a bridge in which meeting or slightly exceeding the baseline, accompanied by a steady full-year posture and constructive qualitative updates, could be sufficient to sustain positive sentiment into the fourth quarter and early next year.
Beyond the print, the majority camp emphasizes that the blend of contractually recurring software revenue with milestone-driven collaboration income can create asymmetry in quarterly outcomes. Because the market is already modeling a sequential step-down from the second quarter’s 58.89 million US dollars, any demonstration of stable software annualized contract value, improved close rates, or incremental enterprise deployments would help validate the recurring element of the model. At the same time, even modest progress updates on partnered assets can reset expectations for the timing of milestone flows, which in turn can move the revenue trajectory higher in subsequent quarters. Bullish analysts argue that this pairing—resilient software economics plus pipeline optionality—supports a constructive medium-term earnings path provided cost discipline persists, and they will be looking for signals on opex containment and capital allocation that extend the trend observed last quarter. In sum, with the directional stance skewed positive and the hurdle for the third quarter not aggressive, the upside scenario rests on steady execution in software and tangible, if incremental, evidence that collaboration programs are advancing toward value-inflecting milestones.Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments